Skip to main content

Table 2 Clinical Trial Design Data

From: Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database

Study type
 Interventional 117 97%
 Expanded Access 4 3%
Trial phase
 NR 43 36%
 Early Phase 1 6 5%
 Phase 1 15 12%
 Phase 1/Phase 2 13 11%
 Phase 2 29 24%
 Phase 2/Phase 3 7 6%
 Phase 3 7 6%
 Phase 4 1 1%
Allocation
 NR 113 93%
 Non-Randomized 18 15%
 Randomized 6 5%
Interventional model
 Single Group Assignment 102 84%
 Parallel Assignment 14 12%
 NR 20 17%
 Crossover assignment 1 1%
Masking (Blinding)
 Open Label 96 79%
 NR 21 17%
 Masked (Blinded) 4 3%
Number of arms
 1 96 79%
 2 11 9%
 3 7 6%
 NR 7 6%
Number of reported primary outcomes
 NR 4  
 1 88
 2 11
 3 10
  ≥ 4 8
Number of reported secondary outcomes
 NR 44  
 1 32
 2 13
 3 6
  ≥ 4 26
  1. NR not regsitered